Literature DB >> 10072111

Myelodysplastic syndromes with nephrotic syndrome.

T Saitoh1, H Murakami, H Uchiumi, K Moridaira, T Maehara, T Matsushima, N Tsukamoto, J Tamura, M Karasawa, T Naruse, J Tsuchiya.   

Abstract

It is sometimes reported that the immunological abnormalities in myelodysplastic syndromes (MDS) induce autoimmune disease (i.e., acute systemic vasculitic syndrome, chronic cutaneous vasculitis, polyneuropathy, relapsing polychondritis, and steroid-responsive pulmonary disorders). We investigated the clinical features of patients with MDS accompanied by nephrotic syndrome. We enrolled 125 patients with MDS who were admitted between January 1979 and May 1996 in this study. The renal function was assessed based on the laboratory data and the findings at the physical examination. The diagnoses of nephrotic syndrome and glomerular disease were established when 24-hr urinary excretion was more than 3.5 g and serum total protein was less than 6.0 g/dl, and when the 24-hr protein excretion was more than 1.5 g. Five patients (4%) had glomerular disease, and three (2.4%) had nephrotic syndrome. Of the five patients with glomerular disease, two had refractory anemia (RA), and three had chronic myelomonocytic leukemia (CMMOL). Three of the total 11 patients with CMMOL were diagnosed as having nephrotic syndrome. Among the CMMOL patients, those with nephrotic syndrome showed higher absolute monocyte numbers than did those without nephrotic syndrome (8830 +/- 4677/microl vs. 3061 +/- 2887/microl, P = 0.03). One CMMOL patient was treated with VP-16 and hydroxyurea. As the white blood cell count in this patient decreased, the 24-hr urine protein excretion and the serum tumor necrosis factor alpha level decreased. The relationship between nephrotic syndrome and CMMOL was not clear. High monocyte count and the serum cytokines in MDS patients may play a partial role in the evolution of glomerulonephritis, and CMMOL may be closely related to nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072111     DOI: 10.1002/(sici)1096-8652(199903)60:3<200::aid-ajh6>3.0.co;2-0

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

Review 2.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

3.  A forgotten cause of kidney injury in chronic myelomonocytic leukemia.

Authors:  Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

4.  Membranous glomerulonephritis in a patient with myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia.

Authors:  Kwang Il Ko; Mi Jung Lee; Fa Mee Doh; Hyang Mo Koo; Chan Ho Kim; Dong Ho Shin; Hyung Jung Oh; Seung Hyeok Han; Shin-Wook Kang; Kyu Hun Choi; Tae-Hyun Yoo
Journal:  Kidney Res Clin Pract       Date:  2013-07-10

Review 5.  [Extramembranous glomerulonephritis and myelodysplastic syndrome: a rare association].

Authors:  Mahtat El Mehdi; Ahmed Alayoude; Mohamed Amine Hamzi; Wafe Arache; Kawtar Hassani; Selim Jennane; Hicham Eddou; Kamal Doghmi; Mohamed Mikdame
Journal:  Pan Afr Med J       Date:  2018-01-30

Review 6.  Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits.

Authors:  Antoine Morel; Marie-Sophie Meuleman; Anissa Moktefi; Vincent Audard
Journal:  Diagnostics (Basel)       Date:  2021-04-15

Review 7.  Glomerular diseases and cancer: evaluation of underlying malignancy.

Authors:  Antonello Pani; Camillo Porta; Laura Cosmai; Patrizia Melis; Matteo Floris; Doloretta Piras; Maurizio Gallieni; Mitchell Rosner; Claudio Ponticelli
Journal:  J Nephrol       Date:  2015-10-26       Impact factor: 3.902

8.  Myelodysplastic syndrome: the other cause of anemia in end-stage renal disease patients undergoing dialysis.

Authors:  Min-Yu Chang; Sheng-Fung Lin; Shih-Chi Wu; Wen-Chi Yang
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.